This article was originally published in The Gray Sheet
$10 mil. equity financing agreement, provides "sufficient operating capital" to enable expeditious implementation of a strategic plan to "reposition the company as a developer and marketer of minimally invasive surgical devices," the firm says. Additional "funding tranches" are anticipated as the plan is implemented and specific milestones are completed, American BioMed notes. The Woodlands, Texas firm says it is now positioned to "aggressively" pursue acquisitions and product commercialization activities. The NIR Group has been retained as the firm's investment banker and financial advisor for acquisitions and strategic planning
You may also be interested in...
American BioMed plans to submit an investigational device exemption in the next 90 days for use of its OmniCath peripheral atherectomy catheter for treatment of hemodialysis arteriovenous (A-V) fistula restenosis.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.